Valion Bio, Inc.
VBIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$500.7K
Close$
$0.30
90.6% downside
Current Fair Value
90.6% downsideOvervalued by 90.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $500,697.00 |
|---|---|
| Enterprise Value | $8.41 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-7.58 |
| Beta | 1.86 |
| Outstanding Shares | 115,419,936 |
Return
| Return on Equity | -232.50% |
|---|---|
| Return on Assets | -30.40% |
| Return on Invested Capital | -37.11% |
Valuation & Multiples
| P/E Ratio | -0.04 |
|---|---|
| PEG | -0.01 |
| Price to Sales | -3.17 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -53.93 |
| Enterprise Value to EBIT | -0.77 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.19 |
| Debt to Equity | 2.36 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-10200.00
Average shareholder expectationRevenue Estimate
$460,000
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-408.00
Average shareholder expectationRevenue Estimate
$460,000
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Valion Bio, Inc.
52 employees
CEO: Michael R. Cavanaugh Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimo...